Journal article
FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies
CE Weeden, B Solomon, M-L Asselin-Labat
CELL DEATH DISCOVERY | NATURE PUBLISHING GROUP | Published : 2015
Abstract
Although the incidence of lung cancer has decreased due to the reduction of tobacco use, lung cancer remains the leading cause of cancer-related death. Lung squamous cell carcinoma represents 30% of lung cancers and only recently have possible drug-targetable mutations been identified in this disease, including fibroblast growth factor receptor 1 (FGFR1) gene amplification and genetic alterations in the phosphoinositide-3 kinase pathway. These discoveries have generated a great interest in the clinic and the initiation of clinical trials using FGFR tyrosine kinase inhibitors to treat FGFR-altered lung cancers. However, preliminary results from these studies have shown that not all patients r..
View full abstractGrants
Funding Acknowledgements
M-LA-L is supported by Australian Research Council Queen Elizabeth II Fellowship. CEW is supported by an Australian Postgraduate Award. BS is supported by a Clinical Research Fellowship from the Victorian Cancer Agency. This work was supported in part by an Australian National Health and Medical Research Council grant to M-LA-L. This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS.